title: [Photodynamic therapy with verteporfin in choroidal neovascularization after refractive surgery].
abstract: OBJECTIVE
  To analyze the results obtained with Photodynamic Therapy (PDT) to treat subfoveal and juxtafoveal Choroidal Neovascularization (CNV) in patients with high myopia corrected by Laser-Assisted in situ Keratomileusis (LASIK) or by implanting a Phakic Intraocular Lens (PIOL).
  
  
  METHODS
  We analyzed the results from 14 highly myopic eyes corrected by LASIK (seven cases) or by PIOL implantation (seven cases), which later developed CNV and were treated by PDT with verteporfin.
  
  
  RESULTS
  Mean Best Corrected Visual Acuity (BCVA) after refractive surgery was 0.45 SD 0.17 (range, 0.2 to 0.8), with residual spherical equivalent (RSE) -0.5 SD 1.8 D (range, 1 to 5.5 D). After CNV appearance, BCVA was 0.10 SD 0.19 (range, 0.025 to 0.7). CNV was treated in all cases by PDT (mean, 2.0 SD 0.8 treatments). After CNV closure, the mean BCVA improved up to 0.22 SD 0.18 (range, 0.1 to 0.63) (RSE -1.4 SD 1.4 D, range, 0.5 to -4 D). Differences in RSE after refractive surgery and after PDT, and differences between BCVA after CNV appearance and final were not statistically significant (p=0.82 and p=0.06, respectively, Student's t test paired data).
  
  
  CONCLUSIONS
  We consider that PDT is effective in achieving closure of CNV in myopic patients after refractive surgery without inducing changes in spherical equivalent.
authors.affiliation: Instituto Oftalmológico de Alicante, Unidad de Retina y Vítreo, Alicante, España. pamatp@yahoo.es
authors.forename: P
authors.initials: P
authors.lastname: Amat-Peral
authors.forename: F
authors.initials: F
authors.lastname: Lugo
authors.forename: J A
authors.initials: JA
authors.lastname: Montero
authors.forename: C
authors.initials: C
authors.lastname: de-la-Vega
authors.forename: J F
authors.initials: JF
authors.lastname: Arévalo
authors.forename: J L
authors.initials: JL
authors.lastname: Alió Y Sanz
mesh_terms: D000328:Adult; D020256:Choroidal Neovascularization / Q000188:drug therapy* / Q000209:etiology*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010778:Photochemotherapy; D017319:Photosensitizing Agents / Q000627:therapeutic use*; D011166:Porphyrins / Q000627:therapeutic use*; D054140:Refractive Surgical Procedures / Q000009:adverse effects*; D000077362:Verteporfin; D055815:Young Adult
chemical_list: D017319:Photosensitizing Agents; D011166:Porphyrins; D000077362:Verteporfin